ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s
ScripChina’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed
ScripLeading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the
ScripIonis licensed global rights to Phase II polycythemia vera (PV) candidate sapablursen to Ono Pharmaceutical on 11 March. The deal provides near-term and longer-term revenue for a drug candidate the an